Search Results
Dec 18, 2025, 09:00 ET DexCom, Inc. Class Action: The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025 - DXCM
and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants
More news about: The Gross Law Firm
Dec 18, 2025, 08:43 ET Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
current-statusiii
More news about: Elanco Animal Health
Dec 18, 2025, 08:30 ET AtomVie Global Radiopharma Secures a Supply Agreement with Ionetix Corporation to Accelerate Ac-225 Radiotherapeutics Development
quality and logistics services combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies, phases I to III, to the commercial markets. AtomVie currently serves international clients conducting clinical studies in over 28 countries worldwide. AtomVie is currently
More news about: AtomVie Global Radiopharma Inc.
Dec 18, 2025, 08:30 ET AtomVie Global Radiopharma Secures a Supply Agreement with Ionetix Corporation to Accelerate Ac-225 Radiotherapeutics Development
quality and logistics services combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies, phases I to III, to the commercial markets. AtomVie currently serves international clients conducting clinical studies in over 28 countries worldwide. AtomVie is currently
More news about: AtomVie Global Radiopharma Inc.
Dec 18, 2025, 08:00 ET OPTICAL CABLE CORPORATION REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS
may include, among other information, (i) statements concerning our outlook for the future, (ii) statements of belief, anticipation or expectation, (iii) future plans, strategies or anticipated events, and (iv) similar information and statements concerning matters that are not historical facts. Such forward-looking
More news about: Optical Cable Corporation
Dec 18, 2025, 04:00 ET Na targach CES 2026 Hisense będzie przewodzić ewolucji wyświetlaczy skoncentrowanej na człowieku
rozwiązaniach IT. W rankingu firmy analitycznej Omdia firma Hisense zajmuje pozycję lidera w segmencie telewizorów 100-calowych i większych (lata 2023 - III kwartał 2025). Jako pierwszy oficjalny partner Mistrzostw Świata w Piłce Nożnej FIFA World Cup 2026™ Hisense konsekwentnie stawia na współpracę ze światem
More news about: Hisense
Dec 18, 2025, 04:00 ET Hisense Pimpin Evolusi Layar Televisi yang Lebih Berorientasi pada Manusia di CES 2026
dan solusi TI pintar. Menurut Omdia, volume penjualan TV Hisense ukuran 100 inci dan lebih berada di peringkat No.1 dunia (periode 2023-Triwulan III-2025). Sebagai sponsor resmi pertama FIFA Club World Cup 2025™, Hisense berkomitmen menjalin kemitraan di bidang olahraga untuk menjangkau audiens global.
More news about: Hisense
Dec 18, 2025, 02:00 ET Uxin Reports Unaudited Financial Results for the Quarter Ended September 30, 2025 and Announces Entry into Definitive Agreement for Financing
Ordinary shares (iii)
More news about: Uxin Limited
Dec 17, 2025, 22:07 ET LRN INVESTOR ALERT: Stride, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
enrollment numbers by retaining "ghost students"; (ii) cutting staffing costs by assigning teachers' caseloads far beyond the required statutory limits; (iii) ignoring compliance requirements, including background checks and licensure laws for its employees, and ignoring federally mandated special education
More news about: Robbins Geller Rudman & Dowd LLP
Dec 17, 2025, 19:00 ET Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
innovative mechanism and robust clinical evidence, its first Phase 3 weight loss clinical study (GLORY-1) was published in NEJM in May 2025iii and incorporated into China's clinical consensus guidelines for obesity and diabetes management. Its two Phase 3 glycemic control clinical studies
More news about: Innovent Biologics
Dec 17, 2025, 18:49 ET U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024 Oct 20;42(30):3593-3605.ClinicalTrials.gov. A Study of Lazertinib With Subcutaneous Amivantamab Compared
More news about: Johnson & Johnson
Dec 17, 2025, 17:43 ET Alpha Aesthetics Partners Proudly Announces Privé Med Spa As Its Newest Partner
equity firm that focuses on building industry-leading companies in the healthcare services sector. Founded by its Chairman and CEO Patrick J. Haynes III in 1986, Thurston Group has returned over $4 billion of invested capital in its 39-year history. Thurston has an extensive track record of partnering
More news about: Alpha Aesthetics Partners
Dec 17, 2025, 17:31 ET Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight
Abivax announced results from the Phase III ABTECT induction trials of obefazimod, which showed significant improvements in quality of life for patients with moderate to severe ulcerative colitis.In July 2025, Abivax announced positive Phase III results from both ABTECT 8-week induction
More news about: DelveInsight Business Research, LLP
Dec 17, 2025, 16:35 ET $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--AWK, SNDA, THS, and WBD
THS) related to its sale to Industrial F&B Investments III Inc. Under the terms of the proposed transaction, TreeHouse shareholders will receive $22.50 in cash per share plus a contingent value right.Click
More news about: Monteverde & Associates PC
Dec 17, 2025, 12:14 ET OpConnect Wins National Supplier of the Year Award from the National Minority Supplier Development Council
OpConnect, a leading provider of electric-vehicle (EV) charging solutions, has been named the 2025 National Supplier of the Year (Class III) by the National Minority Supplier Development Council (NMSDC). The award was announced on November 5, 2025, at the NMSDC Awards Gala in Miami, Florida.
More news about: OpConnect, Inc
Dec 17, 2025, 11:30 ET New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
LOCADE.WARNINGS AND PRECAUTIONSAddiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and
More news about: Indivior PLC
Dec 17, 2025, 10:47 ET RS and MEAN WELL modernize industrial power supplies
for flexible power expansion up to 3,840W, are fully equipped with built-in DC OK relay contacts for basic system monitoring, are compliant with OVC III standards, which can eliminate AC transformer requirements in some applications, and are capable of operating at altitudes up to 5,000m. XDR-E series
More news about: RS
Dec 17, 2025, 10:13 ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DeFi Technologies
other DAT companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly,
More news about: Faruqi & Faruqi, LLP
Dec 17, 2025, 08:40 ET Global Alternative Investment Management LLC Announces Launch of Global Alts LLC - Unicorn Tech Fund III Targeting Late-Stage and High-Growth Technology Unicorns
Unicorn Tech Fund III (the "Fund"), a new private investment vehicle designed to provide qualified investors with access to late-stage, high-growth technology companies—commonly known as "unicorns"—that we believe are reshaping global markets. Unicorn Tech Fund III represents the next
More news about: Global Alternative Investment Management LLC
Dec 17, 2025, 08:00 ET Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment
Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including
More news about: Ginkgo Bioworks
Dec 17, 2025, 07:43 ET PharmaCann Inc. Announces Sale of Certain Colorado Assets to Vireo Growth Inc.
licenses, permits, and authorizations required for the sale of cannabis products in the State of Colorado (subject to regulatory review and approvals); and (iii) certain of the Company's inventory, contracts, and intellectual property, including certain marks associated with the LivWell brand.Completion
More news about: PharmaCann
Dec 17, 2025, 07:19 ET Netflix Welcomes Warner Bros. Discovery Board Recommendation
anticipated benefits of the Merger, including as a result of delay in completing the transaction or integrating the businesses of Netflix and WBD; (iii) Netflix's and WBD's ability to implement their business strategies; (iv) consumer viewing trends; (v) potential litigation relating to the Merger that
More news about: Netflix, Inc.
Dec 17, 2025, 07:04 ET Netflix Welcomes Warner Bros. Discovery Board Recommendation
anticipated benefits of the Merger, including as a result of delay in completing the transaction or integrating the businesses of Netflix and WBD; (iii) Netflix's and WBD's ability to implement their business strategies; (iv) consumer viewing trends; (v) potential litigation relating to the Merger that
More news about: Netflix, Inc.
Dec 17, 2025, 06:50 ET Sealed Air Announces Expiration of "Go-Shop" Period
anticipated benefits or cause the parties to abandon the Transaction; (ii) the possibility that the Company's stockholders may not approve the Transaction; (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement entered into pursuant to the
More news about: Sealed Air
Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
(i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue
More news about: Astellas Pharma Inc.